News
Why are price cap proposals on medicines dangerous to pharmacies and patients?
Supply chain complexity means that upper payment limits and Medicare maximum fair prices will fall disproportionately on pharmacies, leading to closures that threaten patient access to care.
[...]September 30, 2025: Florida agency requests $4 million more for $132 million empty warehouse
Although the state won FDA approval for its importation program in January 2024, it has yet to implement the program.
[...]September 22, 2025: Chinese executives sentenced for shipping 200 kilos of fentanyl precursors into the U.S.
Between November 2022 and June 2023, Amarvel Biotech sold over 200 kilograms of precursor chemicals to U.S. buyers with full knowledge that they would be used to make fentanyl.
[...]Prescription Drug Freight Fraud Report, September 2025
Our analysis of data from June and July revealed hundreds of pharmaceutical shipments that entered the U.S. from facilities no one would expect, including unregistered Chinese exporters and alternative medicine clinics abroad.
[...]September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns FDA
The warning letter was one of about 100 is a new focus on deceptive direct-to-consumer drug advertisements.
[...]September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers
The “green list” will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security.
[...]PSM leads letter in support of an FDA mandate to destroy high-risk imports
PSM led a coalition of organizations urging leaders of the Senate HELP and House Energy and Commerce committees to help strengthen the FDA’s ability to protect Americans from unsafe and counterfeit medicines and medical products.
[...]10 years of fentanyl pills
A decade ago no one had heard of deadly counterfeit prescription pills. Victims’ families bravely spoke up, lobbied, and rallied for change.
[...]September 2, 2025: U.S. compounding restrictions have stemmed a flood of compounded semaglutide and tirzepatide
Chinese companies that supplied U.S. compounders have turned to making generic semaglutide for markets where Novo Nordisk’s main patent is expiring in 2026.
[...]This week: New press draws attention to the dangers of poorly regulated medspas
Elle published an exposé about bad actors and loose regulation in the medical spa industry.
[...]